{
    "info": {
        "nct_id": "NCT03307044",
        "official_title": "Fractional CO2 Laser Therapy for Survivors of Breast Malignancies",
        "inclusion_criteria": "* Women with non-metastatic breast cancer with any hormone receptor and Her 2 neu status who have completed surgery, chemotherapy, and radiation and are currently on endocrine therapy, single agent Herceptin, or observation\n* Symptoms of urogenital atrophy including dyspareunia or vaginal dryness\nHealthy volunteers allowed\nMust be FEMALE",
        "exclusion_criteria": "* Patients with metastatic breast cancer\n* Vaginal stenosis which would not allow vaginal probe to be placed (based on physician exam)\n* Active genital infection at the time of enrollment (if present initially, can be treated and then patient can be re-evaluated for eligibility)\n* Pelvic organ prolapse greater than stage II\n* Prior reconstructive pelvic surgery involving mesh\n* Hormone replacement therapy, vaginal estrogen therapy, DHEA, or biosynthetics within 6 weeks prior to enrollment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women with non-metastatic breast cancer with any hormone receptor and Her 2 neu status who have completed surgery, chemotherapy, and radiation and are currently on endocrine therapy, single agent Herceptin, or observation",
            "criterions": [
                {
                    "exact_snippets": "Women",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "non-metastatic breast cancer",
                    "criterion": "breast cancer metastatic status",
                    "requirements": [
                        {
                            "requirement_type": "metastatic",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any hormone receptor and Her 2 neu status",
                    "criterion": "hormone receptor and Her 2 neu status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "have completed surgery, chemotherapy, and radiation",
                    "criterion": "completion of surgery, chemotherapy, and radiation",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently on endocrine therapy, single agent Herceptin, or observation",
                    "criterion": "current treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": [
                                "endocrine therapy",
                                "single agent Herceptin",
                                "observation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptoms of urogenital atrophy including dyspareunia or vaginal dryness",
            "criterions": [
                {
                    "exact_snippets": "Symptoms of urogenital atrophy",
                    "criterion": "urogenital atrophy symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "dyspareunia",
                    "criterion": "dyspareunia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vaginal dryness",
                    "criterion": "vaginal dryness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with metastatic breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Patients with metastatic breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaginal stenosis which would not allow vaginal probe to be placed (based on physician exam)",
            "criterions": [
                {
                    "exact_snippets": "Vaginal stenosis which would not allow vaginal probe to be placed (based on physician exam)",
                    "criterion": "vaginal stenosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "would not allow vaginal probe to be placed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active genital infection at the time of enrollment (if present initially, can be treated and then patient can be re-evaluated for eligibility)",
            "criterions": [
                {
                    "exact_snippets": "Active genital infection at the time of enrollment",
                    "criterion": "genital infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hormone replacement therapy, vaginal estrogen therapy, DHEA, or biosynthetics within 6 weeks prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Hormone replacement therapy ... within 6 weeks prior to enrollment",
                    "criterion": "hormone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "vaginal estrogen therapy ... within 6 weeks prior to enrollment",
                    "criterion": "vaginal estrogen therapy",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "DHEA ... within 6 weeks prior to enrollment",
                    "criterion": "DHEA",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biosynthetics within 6 weeks prior to enrollment",
                    "criterion": "biosynthetics",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior reconstructive pelvic surgery involving mesh",
            "criterions": [
                {
                    "exact_snippets": "Prior reconstructive pelvic surgery involving mesh",
                    "criterion": "reconstructive pelvic surgery involving mesh",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pelvic organ prolapse greater than stage II",
            "criterions": [
                {
                    "exact_snippets": "Pelvic organ prolapse greater than stage II",
                    "criterion": "pelvic organ prolapse",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "stage"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}